- Home
- ZYME vs STAA Comparison
ZYME vs STAA Comparison
Compare ZYME & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- STAA
- Stock Information
- Founded
- ZYME 2003
- STAA 1982
- Country
- ZYME United States
- STAA United States
- Employees
- ZYME 290
- STAA N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- STAA Ophthalmic Goods
- Sector
- ZYME Health Care
- STAA Health Care
- Exchange
- ZYME Nasdaq
- STAA Nasdaq
- Market Cap
- ZYME 956.0M
- STAA 1.1B
- IPO Year
- ZYME 2017
- STAA N/A
- Fundamental
- Price
- ZYME $13.88
- STAA $22.29
- Analyst Decision
- ZYME Buy
- STAA Buy
- Analyst Count
- ZYME 6
- STAA 7
- Target Price
- ZYME $19.17
- STAA $42.83
- AVG Volume (30 Days)
- ZYME 565.8K
- STAA 639.1K
- Earning Date
- ZYME 03-05-2025
- STAA 02-19-2025
- Dividend Yield
- ZYME N/A
- STAA N/A
- EPS Growth
- ZYME N/A
- STAA 9.97
- EPS
- ZYME N/A
- STAA 0.44
- Revenue
- ZYME $62,199,000.00
- STAA $341,224,000.00
- Revenue This Year
- ZYME $21.53
- STAA $8.37
- Revenue Next Year
- ZYME N/A
- STAA $10.55
- P/E Ratio
- ZYME N/A
- STAA $50.67
- Revenue Growth
- ZYME N/A
- STAA 10.01
- 52 Week Low
- ZYME $7.97
- STAA $21.13
- 52 Week High
- ZYME $17.70
- STAA $52.68
- Technical
- Relative Strength Index (RSI)
- ZYME 48.04
- STAA 37.11
- Support Level
- ZYME $12.80
- STAA $21.25
- Resistance Level
- ZYME $14.63
- STAA $22.78
- Average True Range (ATR)
- ZYME 0.85
- STAA 1.15
- MACD
- ZYME -0.04
- STAA -0.07
- Stochastic Oscillator
- ZYME 25.29
- STAA 27.17
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.